Table 3.
Summary of EGFR-TKI delivered among EGFR mutation positive patients
| |
EGFR mutation positive |
|||||||
|---|---|---|---|---|---|---|---|---|
| |
Low PCV |
High PCV |
||||||
|
(< 2.2 ng/ml) (n= 72) |
(≥ 2.2 ng/ml) (n= 49) |
|||||||
| |
Gefitinib |
Erlotinib |
Gefitinib |
Erlotinib |
||||
| No. | % | No. | % | No. | % | No. | % | |
| First-line |
20 |
28 |
5 |
7 |
23 |
47 |
2 |
4 |
| Second-line |
21 |
29 |
11 |
15 |
14 |
29 |
8 |
16 |
| Third-line |
9 |
12 |
6 |
8 |
3 |
6 |
4 |
8 |
| Further-line |
2 |
3 |
14 |
20 |
2 |
4 |
4 |
8 |
| Unadministered | 20 | 28 | 36 | 50 | 7 | 14 | 31 | 63 |
PCV: pretreatment CYFRA 21–1 value.